SEC ownership of BioNexus Gene Lab Corp

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001737523.

Comparable stake leader

Su-Leng Tan Lee

Disclosed value leader

FIDELION DIAGNOSTICS PTE. LTD.

Comparable rows

9/11

Latest evidence

13 Aug 2026

Top shareholders Insider holders Latest transactions

Public ticker: BGLC on Nasdaq
Parsed ownership sources: 3/4/5, 13D/G, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder: Su-Leng Tan Lee
Ranking: Comparable ownership first, then disclosed value
Comparable ownership rows: 9 of 11
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder: Su-Leng Tan Lee
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date: 13 Aug 2026
Freshness: Most recent filing date in this holder set
Issuer CIK: 0001737523
Issuer location: Kuala Lumpur

Ownership snapshot

Top shareholders of BioNexus Gene Lab Corp (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Su-Leng Tan Lee

Disclosed value leader

FIDELION DIAGNOSTICS PTE....

Comparable rows

9/11

Latest evidence

13 Aug 2026

3/4/5 13D/G 13F Lead comparable stake: 12% 2 rows are not safely comparable across share classes. 13D/G row: Su-Leng Tan Lee Showing 1-8 of 11 holder rows.

Quick read

Su-Leng Tan Lee leads the comparable SEC ownership view at 12%.

9 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Su-Leng Tan Lee's linked filing trail.

Comparable ownership Top 5

Su-Leng Tan Lee 12%

FIDELION DIAGNOSTICS PTE. LTD. 13%

Set Fui Chong 3.3%

Chee Keong Yap 1.1%

Muhammad Azrul bin Abdul Hamid 1.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 11 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Su-Leng Tan Lee	3/4/5 13D/G Chief Executive Officer, Director, 10%+ Owner · Tan Lee Su-Leng 3/4/5 13D/G	12% from 13D/G	$677,418 338,709 shares	—	13 Aug 2026
FIDELION DIAGNOSTICS PTE. LTD.	3/4/5 Greater than 5% holder 3/4/5	13%	$839,584 392,329 shares	—	28 Nov 2025
Set Fui Chong	3/4/5 Chief Financial Officer 3/4/5	3.3%	$193,548 96,774 shares	—	13 Aug 2026
Chee Keong Yap	3/4/5 Director 3/4/5	1.1%	$64,516 32,258 shares	—	13 Aug 2026
Muhammad Azrul bin Abdul Hamid	3/4/5 Director 3/4/5	1.1%	$64,516 32,258 shares	—	13 Aug 2026
Jook Yuen Low	3/4/5 Director 3/4/5	0.59%	$34,780 17,390 shares	—	13 Aug 2026
HRT FINANCIAL LP	13F Company 13F	0.48%	$27,000 14,283 shares	—	30 Jun 2026
UBS Group AG	13F Company 13F	0%	$197 101 shares	—	30 Jun 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 27 Aug 2025.

Buys

Insiders: 0

Sells

Insiders: 0

Net

Shares: 0

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 0 Shares: 0

Window (months)	Buy value	Sell value	Net value
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-15 of 15 reporting-owner rows connected to BioNexus Gene Lab Corp. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

FIDELION DIAGNOSTICS PTE. LTD.

Net 12M change

Latest report

13 Aug 2026

Name	Relationship	Holdings Value	Valuation	Report Date
FIDELION DIAGNOSTICS PTE. LTD.	Greater than 5% holder	$839,584	Mixed	28 Nov 2025
Su-Leng Tan Lee	Chief Executive Officer, Director, 10%+ Owner	$677,418	Mixed	13 Aug 2026
Set Fui Chong	Chief Financial Officer	$193,548	Mixed	13 Aug 2026
Muhammad Azrul bin Abdul Hamid	Director	$64,516	Mixed	13 Aug 2026
Chee Keong Yap	Director	$64,516	Mixed	13 Aug 2026
Jook Yuen Low	Director	$34,780	Mixed	13 Aug 2026
Sook Keng Yeoh	Chief Executive Officer, Director		Mixed	19 Jul 2023
Chak Hua Yew	Director		Mixed	19 Jul 2023
Yee Meng Wong	President, Director		Mixed	19 Jul 2023
Yeat Min Fong	Director		Mixed	19 Jul 2023
Tai Tan Liong	Chief Operating Officer, Director		Mixed	19 Jul 2023
Wei Li Leong	Chief Financial Officer		Mixed	19 Jul 2023
Boon Teong Teoh	Director		Mixed	19 Jul 2023
Chai Ping Lin	Director		Mixed	19 Jul 2023
Teng Fook Fong	Director		Mixed	19 Jul 2023

Recent insider transactions for BioNexus Gene Lab Corp

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Shares	Shares owned	Date	Ownership
Su-Leng Tan Lee	BGLC	Common Shares	Award		338,709	338,709	13 Aug 2026	Direct
Chee Keong Yap	BGLC	Common Shares	Award		32,258	32,258	13 Aug 2026	Direct
Muhammad Azrul bin Abdul Hamid	BGLC	Common Shares	Award		32,258	32,258	13 Aug 2026	Direct
Set Fui Chong	BGLC	Common Shares	Award		96,774	96,774	13 Aug 2026	Direct
Jook Yuen Low	BGLC	Common Stock	Award	1279.1%	16,129	17,390	13 Aug 2026	Direct

^* marks a reported price that did not pass the local price check.

SEC ownership of BioNexus Gene Lab Corp

Top shareholders of BioNexus Gene Lab Corp (13F + 13D/G + 3/4/5)

Su-Leng Tan Lee leads the comparable SEC ownership view at 12%.

Insider trading overview

Insider holders from Forms 3/4/5

Continue from BioNexus Gene Lab Corp ownership

Recent insider transactions for BioNexus Gene Lab Corp